Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies
Comparison of Efficacy of Bismuth Potassium Citrate, Pectin Bismuth Capsules, and Pectin Bismuth Granules in the Treatment of Helicobacter Pylori (Hp) First-line Quadruple Regimen: a Multicenter, Randomized, Prospective, Comparative Clinical Trial
Sponsor: Xijing Hospital of Digestive Diseases
This PHASE4 trial investigates Bismuth and Gastric Cancer and is currently completed. Xijing Hospital of Digestive Diseases leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
May 2021 — Jul 2024 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Xijing Hospital of Digestive Diseases
For direct contact, visit the study record on ClinicalTrials.gov .